O'Reilly Philip, Malhotra Raman
Corneoplastic Unit, Queen Victoria Hospital, East Grinstead, West Sussex, UK.
Orbit. 2011 Jan;30(1):54-7. doi: 10.3109/01676830.2010.535638.
To report on 4 patients who developed delayed hypersensitivity reactions to Restylane(®) SubQ and their management. To our knowledge, no cases of delayed hypersensitivity to Restylane(®) SubQ have been previously reported.
A retrospective case series of 4 patients who were treated with preperiosteal Restylane(®) SubQ to their cheeks, for facial volume augmentation. All 4 patients were subsequently referred with delayed hypersensitivity reactions over a 4-month period.
The hypersensitivity reactions occurred from 1 week to 4 months' post-cheek augmentation using Restylane(®) SubQ. All patients had previously (and some since) been treated with other non-animal stabilized hyaluronic acid (NASHA) products without adverse effect. Hyaluronidase led to fast and effective resolution in all cases, although 2 of the patients required repeat treatment.
Hyaluronidase was effective at treating the inflammatory reaction and breaking up the retained Restylane(®) SubQ in all patients. Although Restylane(®) SubQ should be avoided in these patients, in our experience this does not preclude them from using other similar NASHA products.
报告4例对瑞蓝（Restylane®）皮下注射剂产生迟发型超敏反应的患者及其处理情况。据我们所知，此前尚无瑞蓝皮下注射剂迟发型超敏反应的病例报道。
对4例接受瑞蓝皮下注射剂骨膜前脸颊注射以增加面部容积的患者进行回顾性病例系列研究。所有4例患者在4个月内均出现迟发型超敏反应并前来就诊。
超敏反应发生在使用瑞蓝皮下注射剂进行脸颊填充术后1周~4个月。所有患者此前（部分患者之后也）接受过其他非动物源性稳定透明质酸（NASHA）产品治疗，未出现不良反应。透明质酸酶在所有病例中均能快速有效地缓解症状，尽管有2例患者需要重复治疗。
透明质酸酶在治疗所有患者的炎症反应及分解残留的瑞蓝皮下注射剂方面有效。尽管这些患者应避免使用瑞蓝皮下注射剂，但根据我们的经验，这并不妨碍他们使用其他类似的NASHA产品。
